Platelet glycoprotein IIB/IIIA receptor antagonists. An asset for treatment of unstable coronary syndromes and coronary intervention

European Heart Journal

Volumn 19, Issue 11, 1998, Pages 1608-1616

  Ronner, E ^a   Dykun, Y ^b   Van Den Brand, M J B M ^c   Van Der Wieken, L R ^a   Simoons, Maarten L ^c  

^a ONZE LIEVE VROUWE GASTHUIS   (Netherlands)

^b Government Institution LTMalaya Therapy National Institute of the National Academy of Medical Sciences of Ukraine   (Ukraine)

^c ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; FIBRINOGEN RECEPTOR; FIBRINOGEN RECEPTOR ANTAGONIST; FIBRINOLYTIC AGENT; HEPARIN; LAMIFIBAN; NITRATE; STREPTOKINASE; TICLOPIDINE; TIROFIBAN; TROPONIN T; XEMILOFIBAN;

ANGIOCARDIOGRAPHY; ATHERECTOMY; BLEEDING; DRUG EFFICACY; DRUG SAFETY; GRAFT PATENCY; HEART INFARCTION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; REVIEW; STENT; THROMBOCYTE AGGREGATION; THROMBOCYTOPENIA; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME; UNSTABLE ANGINA PECTORIS;

ANGINA, UNSTABLE; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTIBODIES, MONOCLONAL; DISEASE PROGRESSION; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; MYOCARDIAL INFARCTION; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; RANDOMIZED CONTROLLED TRIALS; SURVIVAL ANALYSIS; THROMBOLYTIC THERAPY; TYROSINE;

EID: 0032212439     PISSN: 0195668X     EISSN: None     Source Type: Journal    
DOI: 10.1053/euhj.1998.1222     Document Type: Review

References (86)

1. [1] Theroux P, Ouimet H, McCans J et al. Aspirin, heparin, or both to treat acute unstable angina. N Engl J Med 1988; 319: 1105-11.
2. [2] Antiplatelet Trialist' Collaboration. Collaborative overview of randomized trials of antiplatelet therapy. I. Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Br Med J 1994; 308: 81-106.
3. [3] The GUSTO IIa Investigators. Randomized trial of intravenous heparin versus recombinant hirudin for acute coronary syndromes. Circulation 1994; 90: 1631-7.
4. [4] The RISC group. Risk of myocardial infarction and death during treatment with low-dose aspirin and intravenous heparin in men with unstable coronary artery disease. Lancet 1990; 3376: 827-30.
5. [5] Tenaglia AN, Fortin DF, Califf RM et al. Predicting the risk of abrupt vessel closure after angioplasty in an individual patient. J Am Coll Cardiol 1994; 24: 1004-11.
6. [6] De Feyter PJ, de Jaegere PP, Serruys PW. Incidence, predictors, and management of acute coronary occlusion after coronary angioplasty. Am Heart J 1994; 127: 643-51.
7. [7] Ellis SG. Percutaneous coronary intervention in the 1990s: results in patients with single or multivessel disease (review). Herz 1992; 17: 18-26.
8. [8] Mark DB, Lam LC, Kerry KL et al. Effects of coronary heart surgery, and medical therapy on employment in patients with coronary artery disease: a prospective comparison study. Ann Intern Med 1994; 120: 111-7.
9. [9] Altmann DB, Popma JJ, Hong MK et al. CPK-MB elevation after angioplasty of saphenous vein grafts (Abstr). J Am Coll Cardiol 1993; 21: 232A.
10. [10] Braden GA, Applegate RJ, Young TM et al. ReoPro decreases creatine kinase elevation following rotational atherectomy: evidence for a platelet dependent mechanism (Abstr). Circulation 1996; 94 (Suppl 1): I-248.
11. [11] Buchbinder MA, Braden GA, Sharma SK et al. A pilot study of ReoPro with rotational atherectomy (RA) to reduce creatine kinase (CK) elevation post procedure (Abstr). Circulation 1996; 94 (Suppl 1): I-197.
12. [12] Kong Jr TQ, Davidson CJ, Meyers SN et al. Prognostic implication of creatine kinase elevation following elective coronary artery interventions. JAMA 1997; 277: 461-6.
13. [13] Redwood SR, Popma JJ, Kent KM et al. 'Minor' CPK-MB elevations are associated with increased late mortality following ablative new-device angioplasty in native coronary arteries. Circulation 1995; 92 (Suppl 1): I-544.
14. [14] Simoons ML, Kootstra J, Van den Brand MJ et al. Minimal myocardial damage during coronary intervention is associated with impaired outcome. In press.
15. [15] Coller BS, Peerschke EL, Scudder LE et al. A murine monoclonal antibody that completely blocks the binding of fibrinogen to platelet produces a thrombastenic state in normal platelets and binds to glycoproteins IIb and/or IIIa. J Clin Invest 1983; 72: 325-38.
16. [16] The Hint trial Group. Early treatment of unstable angina in the coronary care unit: A randomised, double blind, placebo controlled comparison of recurrent ischaemia in patients treated with nifedipine or metoprolol or both. Br Heart J 1986; 56: 400-13.
17. [17] The PARAGON investigators. International, randomized, controlled trial of lamifiban (a platelet glycoprotein IIb/IIIa inhibitor), heparin, or both in unstable angina. Circulation 1998; 97: 2386-95.
18. [18] Chesebro JH, Badimon JJ. Platelet glycoprotein IIb/IIIa receptor blockade in unstable coronary disease. N Engl J Med 1998; 338: 1539-40.
19. [19] The PRISM study investigators. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. N Engl J Med 1998; 338: 1498-505.
20. [20] The PRISM-PLUS study investigators. Inhibition of the platelet glycoprotein Ilb/IIIa receptor with tirofiban in unstable angina and non-Q wave myocardial infarction. N Engl J Med 1998; 338: 1488-97.
21. [21] The PURSUIT trial investigators. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. N Engl J Med 1998; 339: 436-43.
22. [22] Deckers JW. PURSUIT. Presented at the 19th Congress of the European Society of Cardiology; August 24-28, 1997; Stockholm, Sweden.
23. [23] Topol EJ. Platelet glycoprotein IIb/IIIa receptor antagonists in coronary artery disease. Eur Heart J 1996; 17: 9-18.
24. [24] Tcheng JE. Glycoprotein IIb/IIIa receptor inhibitors: putting the EPIC, IMPACT-II, RESTORE, and EPILOG trials into perspective. Am J Cardiol 1996; 78 (Suppl 3A): 35-40.
25. [25] Lefkovits J, Topol EJ. Platelet glycoprotein IIb/IIIa receptor antagonist in coronary artery disease. Eur Heart J 1996; 17: 9-18.
26. [26] Lefkovits J, Plow EF, Topol EJ. Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine. N Engl J Med 1995; 332: 1553-9.
27. [27] Verheugt FWA. In search of a superaspirin for the heart. Lancet 1997; 349: 1409-10.
28. [28] Simoons ML, de Boer MJ, van den Brand MJ et al. Randomized trial of a GP IIb/IIIa platelet receptor blocker in refractory unstable angina. European Cooperative Study Group. Circulation 1994; 89: 596-603.
29. [29] The CAPTURE Investigators. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE study. Lancet 1997; 349: 1429-35.
30. [30] Van de Werf F. More evidence for a beneficial effect of platelet glycoprotein IIb/IIIa-blockade during coronary interventions. Latest results from the EPILOG and CAPTURE trials. Eur Heart J 1996; 17: 325-6.
31. [31] The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med 1994; 330: 956-61.
32. [32] Topol EJ, Califf RM, Weisman HF et al. Randomised trial of coronary intervention with antibody against platelet IIb/IIIa integrin for reduction of clinical restenosis: results at six months. The EPIC Investigators. Lancet 1994; 343: 881-6.
33. [33] Topol EJ, Ferguson JJ, Weisman HF et al. Long-term protection from myocardial ischemic events in a randomized trial of brief integrin P3 blockade with percutaneous coronary intervention. JAMA 1997; 278: 479-84.
34. [34] Califf RM, Lincoff AM, Tcheng JE et al. An overview of the results of the EPIC trial. Eur Heart J 1995; 16 (Suppl L): 43-9.
35. [35] The EPILOG Investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med 1997; 336: 1689-6.
36. [36] Lincoff AM, Tcheng JE, Califf RM et al. Standard versus low dose weight-adjusted heparin in patients treated with the platelet glycoprotein IIb/IIIa receptor antibody fragment abciximab (c7E3) during percutaneous coronary revascularization. Am J Cardiol 1997; 79: 286-91.
37. [37] Tcheng JE, Harrington RA, Kottke-Marchant K et al. Multicenter, randomized, double-blind, placebo-controlled trial of the platelet integrin glycoprotein IIb/IIIa blocker Integrelin in elective coronary intervention. IMPACT Investigators. Circulation 1995; 91: 2151-7.
38. [38] The IMPACT-II Investigators. Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. Lancet 1997; 349: 1422-8.
39. [39] Lefkovits J, Blankenship JC, Anderson KM et al. Increased risk of non-Q wave myocardial infarction after directional atherectomy is platelet dependent: evidence from the EPIC trial. J Am Coll Cardiol 1996; 28: 849-55.
40. [40] The EPISTENT investigators. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein IIb/IIIa blockade. Lancet 1998; 352: 87-92.
41. [41] Serruys PW, De Jaegere P, Kiemeney F et al. A comparison of balloon-expandable stent implantation with balloon angioplasty in patients with coronary artery disease. N Engl J Med 1994; 331: 489-95.
42. [42] Fischman DL, Leon MB, Baim DS et al. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. N Engl J Med 1994; 331: 496-501.
43. [43] Muhlestein JB, Karagounis LA, Treehan S et al. 'Rescue' utilization of abciximab for the dissolution of coronary thrombus developing as a complication of coronary angioplasty. J Am Coll Cardiol 1997; 30: 1729-34.
44. [44] The TIMI IIIB Investigators. Effects of tissue plasminogen activator and a comparison of early invasive and conservative strategies in unstable angina and non-Q-wave myocardial infarction: results of the TIMI IIIB trial. Circulation 1994; 89: 1545-6.
45. [45] Boden WE, O'Rourke RA, Crawford MH et al. Outcomes in patients with acute non-Q myocardial infarction randomly assigned to an invasive as compared with a conservative management strategy. N Engl J Med 1998; 338: 1785-92.
46. [46] Ferry DR, O'Rourke RA, Blaustein AS et al. Design and baseline characteristics of the Veterans Affairs Non-Q-Wave Infarction Strategies in-hospital (VANQWISH) trial. J Am Coll Cardiol 1998; 31: 312-20.
47. [47] Umans VA, Kloeg PH, Bronzwaer J et al. Safety and efficacy of Reo-Pro treatment for patients with unstable angina while awaiting PTCA in a referring clinic. Presented at the 19th Congress of the European Society of Cardiology; August 24-28, 1997; Stockholm, Sweden.
48. [48] Hamm CW, Heeschen C, Goldman BU et al. Value of troponins in predicting therapeutic efficacy of abciximab in patients with unstable angina. Presented at the 47th Annual Scientific Sessions of the American College of Cardiology; March 29-April 1, 1998; Atlanta Georgia, U.S.A.
49. [49] Hamm CW, Heeschen C, Goldman BU et al. Troponin T predicts the benefit of Abciximab in patients with unstable angina in the CAPTURE study. In press.
50. [50] Gold HK, Garabedian HD, Dinsmore RE et al. Restoration of coronary flow in myocardial infarction by intravenous chimeric 7E3 antibody without erogenous plasminogen activators: observations in animals and humans. Circulation 1997; 95: 1755-9.
51. [51] Verheugt FWA. GRAPE. Presented at the 19th Congress of the European Society of Cardiology; August 24-28, 1997; Stockholm, Sweden.
52. [52] DeWood MA, Spores J, Notske R et al. Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction. N Engl J Med 1980; 303: 897-902.
53. [53] Timmis AD, Griffin B, Crick JCP et al. Anisoylated plasminogen streptokinase activator in acute myocardial infarction: a placebo-controlled arteriographic coronary recanalization study. J Am Coll Cardiol 1987; 10: 205-10.
54. [54] Topol EJ. RAPPORT. Presented at the 19th Congress of the European Society of Cardiology; August 24-28, 1997; Stockholm, Sweden.
55. [55] Brenner SJ. RAPPORT. Presented at the 70th Scientific sessions of the American Heart Association; November 9-13, 1997; Orlando Florida, U.S.A.
56. [56] Roux SP, Tschopp TB, Kuhn H et al. Effects of heparin, aspirin and a synthetic platelet glycoprotein IIb-IIIa receptor antagonist (Ro 43-5054) on coronary artery reperfusion and reocclusion after thrombolysis with tissue-type plasminogen activator in the dog. J Pharmacol Exp Ther 1993; 264: 501-8.
57. [57] Gold HK, Garabedian HD, Dinsmore RE et al. Restoration of coronary flow in myocardial infarction by intravenous chimeric 7E3 antibody without erogenous plasminogen activators: observations in animals and humans. Circulation 1997; 95: 1755-9.
58. [58] Simoons ML. Combined therapy with streptokinase and integrilin. Presented at the 70th Scientific sessions of the American Heart Association; November 9-13, 1997; Orlando Florida, U.S.A.
59. [59] Ohman EM, Kleiman NS, Gacioch G et al. Combined accelerated tissue-plasminogen activator and platelet glycoprotein IIb/IIIa integrin receptor blockade with Integrilin in acute myocardial infarction. Results of a randomized, placebo-controlled, dose-ranging trial. IMPACT-AMI Investigators. Circulation 1997; 95: 846-54.
60. [60] Braunwald E. TIMI 14, preliminary results. Presented at the 70th Scientific sessions of the American Heart Association; November 9-13, 1997; Orlando Florida, U.S.A.
61. [61] Kleiman NS, Ohman EM, Califf RM et al. Profound inhibition of platelet aggregation with monoclonal antibody 7E3 Fab after thrombolytic therapy. Results of the Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) 8 Pilot Study. J Am Coll Cardiol 1993; 22: 381-9.
62. [62] Mascelli MA, Lance ET, Lakshmi Damaraju et al. Pharmacodynamic profile of short-term abciximab treatment demonstrates prolonged platelet inhibition with gradual recovery from GP IIb/IIIa receptor blockade. Circulation 1998; 97: 1680-8.
63. [63] Coller BS, Lang D, Scudder LE. Rapid and simple platelet function assay to assess glycoprotein IIb/IIIa receptor blockade. Circulation 1997; 95: 860-7.
64. [64] Coller BS. Monitoring platelet GP IIb/IIIa antagonist therapy, Editorial. Circulation 1998; 97: 5-9.
65. [65] Mascelli MA, Worley S, Veriabo NJ et al. Rapid assessment of platelet function with a modified whole-blood aggregometer in percutaneous transluminal coronary angioplasty patients receiving anti-GP IIb/IIIa therapy. Circulation 1997; 96: 3860-6.
66. [66] Fuster V, Badimon L, Badimon JJ, Chisibro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes. N Engl J Med 1992; 326: 242-50.
67. [67] Fuster V, Badimon L, Badimon JJ, Chisibro JH. The pathogenesis of coronary artery disease and the acute coronary syndromes. N Engl J Med 1992; 326: 310-8.
68. [68] Cannon CP, McCabe CH, Borzak S et al. Randomized trial of an oral platelet glycoprotein IIb/IIIa antagonist, sibrafiban, in patients after an acute coronary syndrome. Results of the TIMI 12 trial. Circulation 1998; 97: 340-9.
69. [69] Cannon CP, Novotny WF, McCabe CH et al. Evaluation of the oral glycoprotein IIb/IIIa antagonist Ro 48-3657 in patients post acute coronary syndromes: primary results of the TIMI 12 trial (Abstr). Circulation 1996; 94 (Suppl 1): 1-552.
70. [70] Simpfendorfer C, Knottke-Marchant K, Topol EJ. First experience with chronic platelet GP IIb/IIIa blockade: a pilot study of Xemilofiban an orally active antagonist in unstable angina patients eligible for PTCA (Abstr). J Am Coll Cardiol 1996; 27 (Suppl A): 242.
71. [71] Simpfendorfer C, Kottke-Marchant K, Lowrie M et al. First chronic platelet glycoprotein IIb/IIIa integrin blockade. A randomized, placebo-controlled pilot study of xemilofiban in unstable angina with percutaneous coronary interventions. Circulation 1997; 96: 76-81.
72. [72] Van den Brand MJBM, Baardman T, Suryapranata et al. Initial experience with BIBU 104XX; a new, oral glycoprotein IIb/IIIa receptor blocker. Presented at the 19th Congress of the European Society of Cardiology; August 24-28, 1997; Stockholm, Sweden.
73. [73] Muller TH, Weisenberger H, Brickl R et al. Profound and sustained inhibition of platelet aggregation by fradafiban, a nonpeptide platelet glycoprotein IIb/IIIa antagonist, and its orally active prodrug, lefradafiban, in man. Circulation 1997; 96: 1130-8.
74. [74] Kereiakes DJ, Runyon JP, Kleiman NS et al. Differential dose-response to oral Xemilofiban after antecedent intravenous abciximab. Circulation 1996; 94: 906-10.
75. [75] Vorchheimer DA, Fuster V. Oral platelet glycoprotein IIb/ IIIa receptor antagonists: the present challenge is safety. Circulation 1998; 97: 312-4.
76. [76] Aguirre FV, Topol EJ, Ferguson JJ et al. Bleeding complication with the chimeric antibody to platelet glycoprotein IIb/ IIIa intergrin in patients undergoing percutaneous coronary intervention. Circulation 1995; 91: 2882-90.
77. [77] Aguirre FV, Ferguson JJ, Califf RM for the EPIC Investigators. Clinical predictors of bleeding complications in high risk angioplasty: results from the EPIC Study Group (Abstr). Circulation 1993; 88: 1-252.
78. [78] Blankenship JC, Helkamp AS, Demko SL et al. Vascular access site complications after percutaneous coronary intervention with glycoprotein IIb/IIIa inhibitor therapy in the EPIC trial (Abstr). J Am Coll Cardiol 1997; 29: 278A.
79. [79] Deckers J, Califf P, Topol EJ et al. Use of abciximab (ReoPro) is not associated with an increase in the risk of stroke: overview of three randomized trials (Abstr). J Am Coll Cardiol 1997; 29 (Suppl A): 241A.
80. [80] Berkowitz SD, Harrington RA, Rund MM et al. Acute profound thrombocytopenia after c7E3 Fab (abciximab) therapy. Circulation 1997; 95: 809-13.
81. [81] Kereiakes DJ, Essell JH, Abbottsmith CW et al. Abciximab associated profound thrombocytopenia: therapy with immunoglobulin and platelet transfusion. Am J Cardiol 1996; 78: 1161-3.
82. [82] Coller BS. A new murine monoclonal antibody reports an activation-dependent change in the conformation and/or microenvironment of the platelet glycoprotein IIb/IIIa complex. J Clin Invest 1985; 76: 101-8.
83. [83] Ellis GE, Tcheng JE, Navetta FI et al. Safety and antiplatelet effect of murine monoclonal antibody 7E3 Fab directed against platelet glycoprotein IIb/IIIa in patients undergoing elective coronary angioplasty. Cor Art Dis 1993; 4: 167-75.
84. [84] Jordan RE, Wagner CL, Mascelli MA et al. Preclinical development of c7E3 Fab; a mouse/human chimeric monoclonal antibody fragment that inhibits platelet function by blockade of GPIIb/IIIa receptors with observations on the immunogenicity of c7E3 Fab in humans. In: Horton MA, ed. Adhesion Receptors as Therapeutic Targets. London: CRC Press, 1996: 281-305.
85. [85] Knight DM, Wagner C, Jordan R et al. The immunogenicity of the 7E3 murine monoclonal Fab antibody fragment variable region is dramatically reduced in humans by substitution of human for murine constant regions. Mol Immunol 1995; 32: 1271-81.
86. [86] Tcheng JE, Kereiakes DJ, George BS et al. Safety of Readministration of Abciximab; Interim Results of the ReoPro Readministration Registry (R3). Presented at the 47th Annual Scientific Sessions of the American College of Cardiology; March 29-April 1, 1998; Atlanta Georgia, U.S.A.